3rd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$640,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in the Senate NDAA, S.2296 - National Defense Authorization Act for Fiscal Year 2026. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. Establishment Inspection Reports. S.1414/H.R._: Expedited Access to Biosimilars Act.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
JOHN MURPHY —
MARK RATNER New Covered Positions Continued: Policy Coordinator-House Energy & Commerce Committee Energy Subcommittee (Rep. Fred Upton); Policy Coordinator-House Energy & Commerce Committee Energy (Rep. Fred Upton); Sr. LA/LA-Rep. Fred Upton; LA-Rep. Joe Schwarz

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); Congressional Budget Office (CBO); SENATE; White House Office; Food & Drug Administration (FDA)

Bills named: S. 1891 (119th), S. 2062 (119th), S. 2296 (119th), S. 1954 (119th), H.R. 3955 (119th), H.R. 4132 (119th), S. 1784 (119th), H.R. 1396 (119th), S. 2027 (119th), S. 1302 (119th), H.R. 1051 (119th), H.R. 1843 (119th), S. 1414 (119th), H.R. 5526 (119th), H.R. 4191 (119th)

Medicare/Medicaid MMM

Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
MARK RATNER New —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act. H.R.4570/S.1097: Interagency Patent Coordination and Improvement Act of 2025.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
MARK RATNER New —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Justice, Dept of (DOJ); Federal Trade Commission (FTC)

Bills named: H.R. 3269 (119th), H.R. 3152 (119th), S. 2276 (119th), S. 43 (119th), S. 1096 (119th), H.R. 4570 (119th), S. 1041 (119th), S. 1040 (119th), S. 1546 (119th), H.R. 3160 (119th), S. 1097 (119th), S. 1553 (119th)

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Quotas on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
JOHN MURPHY —
MARK RATNER New —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Commerce, Dept of (DOC); Food & Drug Administration (FDA); U.S. Customs & Border Protection; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); SENATE; Natl Economic Council (NEC); U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.